Pancreatic cancer patients with BRCA1/BRCA2 mutations are uniquely positioned to benefit from platinum-based chemotherapies (PtCh) like FOLFIRINOX due to their tumors' defective homologous recombination repair (HRR) mechanisms, which leave them vulnerable to DNA-damaging agents [8]. Here, BRCA1 is linked to familial pancreatic carcinoma.